Navigation Links
Changes in local health care markets affect national patient safety project
Date:6/20/2008

A national patient safety initiative involving major corporate employers and employer health care coalitions may set common goals, but success relies greatly on regional health care players and local market factors for actual implementation, says a recent study.

"While employers and coalitions set critical goals nationwide to improve patient safety, actual success depends greatly on individual hospitals and their characteristics, and intricate parts of the goals themselves," said lead author Dennis Scanlon, professor of health policy and administration at Penn State.

The Leapfrog Group, composed of more than 100 Fortune 500 companies and other large employers, formed in 2000 to reduce preventable medical mistakes by giving consumers and health care purchasers information about patient safety. The group's initiative originally focused on three specific areas of improvement, or "leaps": computerized entry of physician medication orders; hiring intensive care specialists in hospital intensive care units; and referring patients who need procedures, i.e. surgery, to hospitals with significant experience at achieving quality outcomes.

The idea was that local employers who provide health care to employees would encourage area hospitals in meeting Leapfrog standards to improve patient safety. The hospitals would report safety information publicly, which would attract employee patients. Employers would encourage employees to use Leapfrog-compliant hospitals. Overall, the number of medical errors would decline, patient health would improve and costs could possibly stabilize or go down.

Health coalitions, including the National Business Coalition on Health, were brought into the initiative to establish regional markets that would coordinate the hospitals and work together to achieve the Leapfrog goals. Between 2001 and 2006, 31 regional markets containing 57 percent of all urban hospitals in the United States were established.

Scanlon, Jon Christi
'/>"/>

Contact: Vicki Fong
vfong@psu.edu
814-865-9481
Penn State
Source:Eurekalert

0

GOOD

Page: 1 2 3 4

Related medicine news :

1. Lifestyle Changes Affect Cancer Genes
2. LIVESTRONG.COM Survey Reveals 86 Percent of Americans Attempt Changes to Improve Their Health but Less Than Half are Successful
3. Complex changes in the brains vascular system occur after menopause
4. EyeCity.com, Inc. Changes Ownership and Moves Into a New Direction
5. Cardiologists Warn Proposed Changes Would Close Outpatient Cardiac Cath Labs
6. Lifestyle Changes Can Keep Diabetes at Bay for 14 Years
7. Lilly Announces Changes in Key Leadership Roles
8. Mergent, Inc. Announces Changes to the HealthShares(TM) Composite Index, Dermatology and Wound Care Index and Orthopedic Repair Index - Correction
9. Mergent, Inc. Announces Changes to the HealthShares(TM) Composite Index, HealthShares(TM) Dermatology and Wound Care Index and HealthShares(TM) Orthopedic Repair Index
10. Mergent, Inc. Announces Changes to the HealthShares(TM) Composite, Enabling Technologies, Autoimmune-Inflammation, Cancer, Cardiology and Neuroscience Indexes
11. Lumenis Announces changes in Lumenis Vision Strategic Business Unit
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine Technology:New Analytical Training Lab Standardizes on Waters Innovative Technologies to Achieve Educational Goals 2New Analytical Training Lab Standardizes on Waters Innovative Technologies to Achieve Educational Goals 3New Analytical Training Lab Standardizes on Waters Innovative Technologies to Achieve Educational Goals 4Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 2Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 3Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 4Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 5Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 6Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 7Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 8Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 9Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 10AdvanDx Receives FDA 510(k) Clearance for 90 Minutes PNA FISH(R) Protocol for Identifying Staphylococcal Bloodstream Pathogens 2AdvanDx Receives FDA 510(k) Clearance for 90 Minutes PNA FISH(R) Protocol for Identifying Staphylococcal Bloodstream Pathogens 3Kool Smiles Relies on Wyse Technology Virtual Clients to Improve Patient Care and Security of Electronic Health Records 28EHRs 29 53831 1Kool Smiles Relies on Wyse Technology Virtual Clients to Improve Patient Care and Security of Electronic Health Records 28EHRs 29 53831 2Kool Smiles Relies on Wyse Technology Virtual Clients to Improve Patient Care and Security of Electronic Health Records 28EHRs 29 53831 3Kool Smiles Relies on Wyse Technology Virtual Clients to Improve Patient Care and Security of Electronic Health Records 28EHRs 29 53831 4Kool Smiles Relies on Wyse Technology Virtual Clients to Improve Patient Care and Security of Electronic Health Records 28EHRs 29 53831 5Former Microsoft Healthcare Executive Joins iMedExchange 53828 1Former Microsoft Healthcare Executive Joins iMedExchange 53828 2Gold Standard Elsevier Launches MedCounselor Consumer Drug Information Modules 53825 1Gold Standard Elsevier Launches MedCounselor Consumer Drug Information Modules 53825 2Gold Standard Elsevier Launches MedCounselor Consumer Drug Information Modules 53825 3